DOR: 11.4 monthsORR by disease subtypeENKTL: 63.2%ALCL ALK-: 53.8%ALCL ALK+: 42.9%PTCL NOS: 17.9%PD-L1 ≥50% enriched (ORR 53.3% vs. 25%). Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.